Skip to main content
PROTEOME SCIENCES PLC logo

PROTEOME SCIENCES PLC — Investor Relations & Filings

Ticker · PRM ISIN · GB0003104196 LEI · 213800Q62ICXANKU2986 IL Professional, scientific and technical activities
Open in API
Filings indexed 279 across all filing types
Latest filing 2017-06-08 Regulatory Filings
Country GB United Kingdom
Listing IL PRM

About PROTEOME SCIENCES PLC

https://www.proteomics.com/

Proteome Sciences PLC is a specialized Contract Research Organization (CRO) focused on applied proteomics and peptidomics. The company provides comprehensive mass spectrometry-based analytical services to support drug discovery, development, and biomarker identification for precision medicine. Its services cover the full workflow from sample preparation and proteome characterization to bioinformatics data interpretation and reporting, handling diverse biological samples. A key offering is its proprietary TMT® and TMTpro® isobaric tags, which the company invented, developed, and exclusively manufactures for multiplexed protein quantification. These reagents are distributed globally to the mass spectrometry community. The company serves the biopharmaceutical sector, operating under ISO 9001:2015 and Good Clinical Laboratory Practice (GCLP) standards for its targeted assays.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1169 characters) and contains an RNS Number ('5934H') and the source 'The company news service from the London Stock Exchange'. The content announces a 'Price Monitoring Extension' related to an auction call period, which is a specific, non-standard market operational announcement. It does not contain detailed financial results (ER, IR, 10-K) or management/governance details. Since it is a specific regulatory/market notice that doesn't fit the other specific categories (like DIRS, DIV, MANG), the most appropriate fallback category for miscellaneous regulatory announcements is 'Regulatory Filings' (RNS).
2017-06-08 English
Director/PDMR Shareholding
Major Shareholding Notification Classification · 1% confidence The document is clearly identified by the header 'RNS Number : 0587F' and concludes with the statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content details a 'Director/PDMR Shareholding' transaction, specifically a purchase of shares by an entity related to a director. This type of insider transaction disclosure is a standard regulatory announcement. While it relates to director dealings (DIRS), the primary nature of the filing itself, as indicated by the RNS header and footer, points to a general regulatory announcement. However, the specific content (Director/PDMR Shareholding) aligns perfectly with the definition of Director's Dealing (DIRS). Since DIRS is a more specific category than the general RNS fallback, DIRS is the most appropriate classification for the substance of the filing, even though it is distributed via RNS.
2017-05-15 English
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document is identified by the 'RNS Number' header and contains a notification regarding 'Director/PDMR Shareholding'. This filing details the purchase of ordinary shares by an entity (Vulpes Life Sciences Fund) that is closely associated with a Director (Martin Diggle) of the issuer (Proteome Sciences plc). This type of insider transaction reporting falls directly under the definition of Director's Dealing (DIRS). Although it is distributed via RNS, the specific content dictates the DIRS classification over the general RNS fallback.
2017-05-10 English
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document begins with an 'RNS Number' and the date '05 May 2017', indicating a regulatory announcement. The content explicitly details share purchases by a major shareholder ('Vulpes Life Sciences Fund') and the resulting change in interest for a Director/PDMR ('Martin Diggle'). This type of filing, reporting personal share transactions by company directors and executives, directly corresponds to the definition of Director's Dealing. The filing code for Director's Dealing is DIRS. Although it is distributed via RNS, the specific nature of the content overrides the general RNS fallback.
2017-05-05 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is clearly identified by the header 'RNS Number : 2266E' and the closing statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content details a 'TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES', which is a regulatory filing concerning changes in significant share ownership (crossing the 5% threshold). This aligns directly with the definition for Major Shareholding Notification (MRQ). Although RNS is mentioned, MRQ is the more specific classification for this type of disclosure.
2017-05-04 English
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document is clearly identified by the 'RNS Number' header and the concluding statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content details a 'Director/PDMR Shareholding' transaction, specifically a purchase of ordinary shares by an entity associated with a director (Vulpes Life Sciences Fund, associated with Martin Diggle). This type of insider transaction reporting falls under the category of Director's Dealing (DIRS). Although it is an RNS filing, DIRS is the more specific classification for this content type.
2017-05-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.